Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2

Completed

• Conditions: Triple Negative Breast Cancer
• Interventions: Drug: Cisplatin; Drug: Paclitaxel

• Registration Number: NCT01982448
• Lead Sponsor: Dana-Farber Cancer Institute

Brief Summary

This is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic response to preoperative chemotherapy.

Detailed Description

Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response (residual cancer burden (RCB)-0/1) to singleagent cisplatin or paclitaxel.

This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score \>=33. Crossover to an alternative chemotherapy was offered if there was inadequate response.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2013-10-28
• Study First Submitted QC: 2013-11-04
• Study First Posted: 2013-11-13
• Study Start: 2014-04
• Primary Completion: 2019-01
• Study Completion: 2020-08
• Results First Submitted: 2021-02-24
• Results First Submitted QC: 2021-05-25
• Results First Posted: 2021-06-18
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-04
• Last Update Posted: 2024-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 147

Inclusion Criteria

1. Participants must meet the following criteria on screening examination to be eligible to participate in the study
2. Pathologic documentation of invasive breast cancer by biopsy (FNA alone is not adequate).
3. AJCC clinical stage I with T1 > 1.5 cm, stage II or III invasive breast cancer.
4. Participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER2-positive.
5. Tumors must be HER2 negative defined as HER2 0 or 1+ by immunohistochemistry (IHC) assays and /or lack of gene amplification by FISH defined as a ratio < 2 on invasive tumor by local review.
6. ER and PgR status by IHC must be known. Tumor must be ER and PR negative (≤5% staining) by local review.
7. Known BRCA1/2 (BReast CAncer) status is not required for study entry. However patients known to have a germline deleterious BRCA1/2 mutation should be encouraged to consider a preoperative trial specifically designed for BRCA1/2 carriers, if available.
8. Breast imaging should include imaging of the ipsilateral axilla. For subjects with a clinically positive axilla, a needle aspiration, core biopsy or SLN procedure will be performed to confirm the presence of metastatic disease in the lymph nodes.

For patients with a clinically negative axilla, baseline assessment of the axilla will be performed at the discretion of the treating investigator.

For patients with pathologically positive axillary lymph nodes prior to preoperative therapy, a level I and II lymph node dissection at the time of definitive surgery is recommended.

9. Patients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 years.

10. Women ≥ 18 years of age. 11. ECOG performance status ≤1 (see Appendix A). 12. Laboratory Evaluation

11. Absolute neutrophil count (ANC) ≥ 1,500 / mm3

12. Platelet count ≥ 100,000/ mm3

13. Bilirubin ≤ 1.5x upper limit of normal (ULN), for patients with Gilbert syndrome, direct bilirubin will be measured instead of total bilirubin

14. ALT, AST ≤3.0 x ULN ALK Phos <2.5 x ULN

15. Creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 cc/min

16. Hemoglobin ≥ 9 mg/dl

17. Use of an effective means of contraception is required in subjects of childbearing potential since study agents are known to be teratogenic. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

18. Ability to understand and the willingness to sign a written informed consent document

19. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy and did not receive prior chemotherapy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

20. Patient must be willing to undergo mandatory research biopsy and blood draw. Prior to biopsy procedures patients must be able to be off medications that could increase the risk of bleeding

Read More

Exclusion Criteria

1. Participants with axillary adenopathy only are not eligible for this study.
2. Prior chemotherapy: Prior non-taxane or platinum containing chemotherapy will be allowed if the prior exposure was at least 5 years ago and the exposure is thought not to potentially interact with the primary outcome of the trial or put the patient at undue risk, and should be reviewed with study PI on a case by case basis.
3. Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy.
4. Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for DCIS or breast conserving treatment and hormonal therapy for DCIS or invasive breast cancer.
5. Ongoing use of any other investigational or study agents.
6. Peripheral neuropathy of any etiology > grade 1 (NCI CTCAE Version 4.0- Appendix B)
7. Significant hearing loss that would prevent cisplatin administration.
8. Renal dysfunction for which exposure to cisplatin would be unsafe or require cisplatin dose modification (i.e., Cre > 1.5 mg/dl or GFR < 60 cc/min).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: Cisplatin	Cisplatin	Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
Arm B: Paclitaxel	Paclitaxel	Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Pathologic Response by HR-deficiency (HRD) Status	Evaluated after definitive breast surgery, up to 4-5 months from enrollment.	Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). Responders are defined as RCB 0/1 and non-responders as RCB 2/3. Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score \>/= 33.

Secondary Outcome Measures

Name	Time	Method
Number With Pathologic Complete Response (pCR) by HR-deficiency (HRD) Status	Evaluated after definitive breast surgery, up to 4-5 months from enrollment.	Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). pCR is defined as RCB-0. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score \>/= 33.
Positive Predictive Value (PPV) of HRD Score	Evaluated after definitive breast surgery, up to 4-5 months from enrollment.	Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). Responders are defined as RCB 0/1 and non-responders as RCB 2/3. Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score \>/= 33.; PPV was calculated as the probability of pathological response among the HRD positive group.
Number of Pathologic Response	Evaluated after definitive breast surgery, up to 4-5 months from enrollment.	Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). Responders are defined as RCB 0/1 and non-responders as RCB 2/3. Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score \>/= 33.
Number With Pathologic Response	Evaluated after definitive breast surgery, up to 4-5 months from enrollment.	Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). Responders are defined as RCB 0/1 and non-responders as RCB 2/3. Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score \>/= 33.

Trial Locations

Locations (20)

Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States

Indiana University- Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States

Duke University; 🇺🇸 Durham, North Carolina, United States

Universtiy of Pittsburgh- Magee-Womens Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States

University of Alabama; 🇺🇸 Birmingham, Alabama, United States

Vanderbilt-Ingram Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

South Shore Hospital; 🇺🇸 Weymouth, Massachusetts, United States

Memorial Sloan Kettering Cancer Center-Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Cancer Center-Monmouth; 🇺🇸 Middletown, New Jersey, United States

Memorial Sloan Kettering Cancer Center-Commack; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center-Sleepy Hollow; 🇺🇸 Sleepy Hollow, New York, United States

Memorial Sloan Kettering Cancer Center-Rockville Centre; 🇺🇸 Rockville Centre, New York, United States

Memorial Sloan Kettering Cancer Center-West Harrison; 🇺🇸 Harrison, New York, United States

University of North Carolina- Lineberger Cancer Center; 🇺🇸 Chapel Hill, North Carolina, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

University of Washignton; 🇺🇸 Seattle, Washington, United States

Seattle Cancer Alliance at EvergreenHealth; 🇺🇸 Kirkland, Washington, United States